Actively Recruiting
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2023-10-23
1200
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
Sponsors
F
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead Sponsor
P
Politecnico di Milano
Collaborating Sponsor
AI-Summary
What this Trial Is About
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".
CONDITIONS
Official Title
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent provided by the patient or legally acceptable representative before study procedures
- Patients aged 18 years or older at the time of consent
- Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV), planned to receive or already treated with innovative therapies (immunotherapy, targeted therapies, next generation therapies)
You will not qualify if you...
- Taking other unapproved antineoplastic therapies concurrently
- Have not received any oncological systemic innovative therapy
- Received only local treatments such as surgery or radiotherapy without systemic innovative therapies
- Received only standard chemotherapy
- Received treatment therapies before 2010
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Actively Recruiting
Research Team
A
Arsela Prelaj, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here